Timber Pharmaceuticals to Host Conference Call Discussing Positive Topline Results from Phase 2b CONTROL Study of Congenital Ichthyosis for Lead Asset, TMB-001

Rhea-AI Summary

Timber Pharmaceuticals (TMBR) announced a conference call on November 22, 2021, at 10:00 am ET to discuss positive topline results from its Phase 2b CONTROL Study focused on treating Congenital Ichthyosis with their lead product, TMB-001. CEO John Koconis and CMO Alan Mendelsohn will present details related to the study's outcomes. The call will be accessible via dial-in and live webcast, with a replay available on Timber's website.

Positive

• Positive topline results from Phase 2b CONTROL Study for TMB-001.
• Focused on a rare dermatologic disease, targeting growth in specialized markets.

Negative

• None.

Call to be held on Monday, November 22^nd at 10:00am ET

BASKING RIDGE, NJ, Nov. 17, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that it will host a conference call for investors and shareholders to discuss the positive topline results from its recently completed Phase 2b CONTROL Study of Congenital Ichthyosis for its lead asset, TMB-001. The call will be hosted by Timber’s Chief Executive Officer, John Koconis, and Chief Medical Officer, Alan Mendelsohn, M.D.

Conference Call Information

When: Monday, November 22nd at 10:00am ET

Dial in: (833) 685-0983 and ask to be joined into the Timber Pharmaceuticals call.

There will also be a live webcast of the conference call which can be accessed at:

https://services.choruscall.com/mediaframe/webcast.html?webcastid=2JQhJLIU

For those unable to participate in the live conference call, a replay will be archived and available on Timber’s website under the Investor Relations tab at www.timberpharma.com .

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and other sclerotic skin diseases. For more information, visit www.timberpharma.com.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 as well as other documents filed by the Company from time to time thereafter with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information, contact:

Timber Pharmaceuticals, Inc.
John Koconis
Chairman and Chief Executive Officer
jkoconis@timberpharma.com

Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com

Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com

FAQ

What are the topline results from Timber Pharmaceuticals' CONTROL Study?

The topline results indicate positive outcomes for TMB-001 in treating Congenital Ichthyosis.

When will Timber Pharmaceuticals hold the conference call to discuss study results?

The conference call is scheduled for November 22, 2021, at 10:00 am ET.

How can I access the Timber Pharmaceuticals conference call?

You can dial in at (833) 685-0983 or access the live webcast through their website.

What is the significance of TMB-001 in Timber Pharmaceuticals' portfolio?

TMB-001 is their lead asset aimed at treating Congenital Ichthyosis, a rare dermatologic disease.

What potential market impact does Timber Pharmaceuticals' study results have?

Positive study results could enhance Timber’s position in the niche market of rare dermatologic treatments.